Oramed Pharmaceuticals Inc. (ORMP) Stock Grade

About Oramed Pharmaceuticals Inc.'s fundamentals

Oramed Pharmaceuticals is a small-cap biotech company with a $118.0 million market capitalization that shows an extremely low P/E ratio of 1.8, suggesting either significant undervaluation or earnings instability typical of early-stage pharmaceutical firms. The company reported zero year-over-year revenue growth, indicating stagnant top-line performance, though it generated a notably high net margin of 3202.5% and return on equity of 32.1%, metrics that likely reflect minimal revenues and irregular profitability rather than sustainable operational strength. The company does not pay a dividend, which is common for biotech firms prioritizing cash preservation for research and development activities.